



Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA
02210-1862
Tel: 617-341-6100
www.vrtx.com

Notice Regarding Adjustment of 340B Prices for Select Products of Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated (“Vertex”) has recalculated its 340B ceiling prices for the period from Q2 2021 through Q4 2021 for the products listed below due to the recalculation of an estimated provisional 340B ceiling price. Vertex has asked the Office of Pharmacy Affairs (OPA) within HRSA to post this Notice on the public website to ensure transparency by providing access to information about Vertex’s recalculation affecting certain 340B Covered Entities for the impacted product(s).

Vertex has determined the credit amount owed to each affected covered entity. Vertex will be working through Apexus, the HRSA 340B Prime Vendor, to issue refunds for each affected Covered Entity. Refunds will be issued either to a Covered Entity’s validated wholesaler pharmacy account when one can be identified, or a check will be issued to Covered Entities whose wholesaler account cannot be identified.

NDC	Product Description
51167-0106-02	TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor 50 mg/25 mg/37.5 mg; ivacaftor 75 mg) 84ct

If a Covered Entity believes they are due a refund and are not contacted by Apexus by March 31, 2022, you may contact Beth DeStephens, Vertex Director Price Reporting and Rebate Operations at beth_destephens@vrtx.com